Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price ...

Shares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigatio ...

The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) – Equities researchers at Zacks Small Cap issued their Q2 2025 ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $23.11 which represents a decrease of $-2.96 or -11.35% from the prior close of $26.07. The stock opened at $26.15 and ...

Sarepta Therapeutics has turned to dealmaking to restock a drug pipeline analysts worried was growing thin, announcing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fmr LLC cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 10.9% in the third quarter, ...